"Julpar " The main partner of the 14th session of the AIM Investment Summit 2025

Abu Dhabi, March 19/ WAM/ The AIM Investment Summit announced its partnership with Julphar Gulf Pharmaceutical Industries, as the “main partner” for the global manufacturing axis- medicines and health care “, which has the support of the Emirates Drug Corporation, and this comes within the activities of its 14th session, which will be held from 7 to 9 April 2025, at the Denik Abu Dhabi Center.
The summit has the support of more than 400 local, international and international partners, with the aim of unifying efforts and enhancing joint cooperation, highlighting the role of investment in advancing economic development, stimulating innovation, and enhancing the sustainability of vital sectors.
This strategic partnership between the two parties aims to enhance the means of joint action, provide an ideal platform for participants to exchange experiences and ideas, and enhance sustainable growth and digital transformation in the manufacturing sector.

It also contributes to the establishment of the UAE’s position as a global center for trade and manufacturing, especially in the fields of health care products and services, and making it a destination for innovation that elevates the quality of life, as well as its role as a gateway to facilitate the flow of foreign direct investment in the health sector.
Basil Ziada, CEO of Julphar Al Khaleej Pharmaceutical Industries, expressed pride that Julphar be among the partners of the Emirates Drug Corporation and the AIM Investment Summit, with the aim of supporting development strategies, stimulating teamwork, and enhancing partnerships to improve fair access to high -quality health products, which contributes to enhancing global, regional and national health security.
For his part, Dawood Al -Shizawi, President of the AIM International Foundation and the organizing committee of the AIM Investment Summit, stressed the importance of this partnership and its role in supporting the goals of the summit, noting that cooperation with a leading company like Julphar enhances efforts to develop the industrial sector, and supports the summit vision in building a sustainable investment system that contributes to achieving economic development at the global level.

He also stressed the vital role played by the drug manufacturing sector in supporting national economies, promoting health security, and providing innovative solutions that contribute to improving the quality of life, noting that this partnership represents a strategic step towards developing the drug industry and attracting more investments to this vital field.
It is worth noting that the global manufacturing axis is one of the AIM Investment Summit 2025, and searches under the slogan “From Industry 4.0 to Industry 5.0: Benefit from the industry and reviving advanced factories”, the performance of the environmental system for manufacturing and supporting the innovation of products, operational efficiency and sustainability, by reducing handicrafts, improving the use of resources and ensuring workers’ safety, contributes to enhancing productivity and ability Competitiveness, and enabling companies to face future challenges and unexpected turmoil.
The global manufacturing axis highlights the pharmaceutical industry is one of the main engines of innovation in the field of manufacturing, as it depends on the latest technologies such as smart manufacturing, graphic analysis, and automated operation to ensure the highest levels of quality and efficiency.

With the adoption of the techniques of the Fifth Industrial Revolution, pharmaceutical factories can enhance their productivity, accelerate searches and development, and reduce waste, which helps in meeting the increasing demand for drugs at reasonable prices, as well as achieving long -term sustainability.

• For more: Follow Khaleejion 24 Arabic, Khaleejion 24 English, Khaleejion 24 Live, and for social media follow us on Facebook and